NASDAQ$GOCO

GoHealth Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

GoHealth's Q3 2024 performance reflected a strategic transformation towards a Medicare engagement company, marked by revenue decrease, increased submissions, net income improvement, and strategic acquisition of e-TeleQuote.

GoHealth reported a decrease in net revenues to $118.3 million, but net income improved significantly to $15.4 million. Submissions increased by 2.9% to 166,195. The company completed the acquisition of e-TeleQuote, which added $90.5 million in contract assets and $22.5 million in cash, and recorded a $77.4 million gain on bargain purchase.

  • Net revenues for Q3 2024 were $118.3 million, a decrease of $13.7 million year-over-year.
  • Submissions for Q3 2024 increased by 2.9% to 166,195.
  • Net income for Q3 2024 was $15.4 million, a significant improvement from a net loss of $56.2 million in the prior year period.
  • The acquisition of e-TeleQuote added $90.5 million in contract assets and $22.5 million in cash, with a gain on bargain purchase of $77.4 million.

Headline financials

Total Revenue

$118M

Previous: $132M-10.4%
EPS

$0.46

Previous: -$2.61+117.6%
Adjusted EBITDA Margin

-10.2%

No prior period
EBITDA

$60.9M

No prior period
Adjusted EBITDA

-$12.1M

No prior period
Direct Op. Cost of Submission

$110M

No prior period
Sales/Direct Cost of Submission

1.1

No prior period
Sales per Submission

$702.00

No prior period
Direct Operating Cost per Submission

$663.00

No prior period
Submissions

166.2K

No prior period
Capital Expenditures

-$4.25M

Previous: -$3.43M-24.1%
Free Cash Flow

$6.78M

Previous: -$23.9M+128.3%
Net Income

$6.78M

Previous: -$23.9M+128.3%
Operating Income

-$42.7M

Previous: -$38M-12.4%
Gross Profit

$98.6M

Previous: $96M+2.7%
Cash & Equivalents

$35.5M

Previous: $26.4M+34.6%
Total Assets

$1.34B

Previous: $1.44B-6.7%
Stock-Based Comp

$2.86M

Previous: $2.17M+31.6%

Revenue & EPS history

GoHealth · Revenue · Quarterly

$118M

Q3 2024-10.4%vs Q3 2023
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Revenue by segment

GoHealth · $11.9M total across 4 segments · Q1 2026

  • Medicare Agency Revenue
    $9.8M
  • Other Non-Agency Revenue
    $1.76M
  • Medicare Non-Agency Revenue
    $200K
  • Other Agency Revenue
    $155K

Forward guidance

GoHealth is seeing unprecedented disruption, with over two million consumers losing coverage and more than six million experiencing reduced benefits.

Tailwinds

  • Investments in AI-driven technology
  • Expanded agent network
  • Focus on consumer engagement
  • Positioned to lead through market changes
  • Delivering both growth and improved customer experience

Headwinds

  • Over two million consumers losing coverage
  • More than six million experiencing reduced benefits
  • Broader market challenges
  • Competitive landscape shifts
  • Revenue decrease

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-7.7%

Avg return

Earnings day

-9.0%

Avg return

5 days after

-6.6%

Avg return

30 days after

26%

6 / 23 earnings

Positive

+32.2%

Q1 2023

Best reaction

-45.5%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.5%
Q3 2025-24.4%-32.0%-12.8%
Q2 2025-9.0%-7.6%-23.8%
Q1 2025-0.6%-17.4%-21.4%
Q4 2024-14.4%-14.9%-32.8%
Q3 2024-6.6%-0.4%-15.4%
Q2 2024-21.4%-28.3%-34.0%
Q1 2024-8.0%-11.1%+2.2%
Q4 2023-13.0%-25.7%-27.0%
Q3 2023+2.3%+6.7%+7.4%
Q2 2023+6.8%+6.3%-17.2%
Q1 2023+32.2%+44.8%+99.5%
Q4 2022-19.9%-6.2%-18.5%
Q3 2022-16.7%-9.4%+95.3%
Q2 2022-31.5%-43.3%-57.0%
Q1 2022+11.1%+4.9%+6.5%
Q4 2021+23.7%+37.7%-9.8%
Q3 2021+1.1%-4.7%-18.1%
Q2 2021-45.5%-42.2%-34.7%
Q1 2021-2.7%-5.6%-4.0%
Q4 2020-14.9%-16.9%-4.1%
Q3 2020-14.9%-15.1%+1.8%
Q2 2020-10.5%-18.5%-27.1%
Q1 2020
Q4 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro